Skin Toxicity Clinical Trial
Official title:
Evaluation of Novel Skin Care Products for the Management of Immunotherapy- Related Dermatologic Toxicities
Notwithstanding the continuous progress in cancer treatment, patients with cancer still have to cope with quality of life (QoL) - impairing complications. Especially an extensive spectrum of dermatologic toxicities has been associated with cancer treatments. The number and type of cutaneous toxicities have evolved over the past 50 years, paralleling the development of new immunomodulatory agents. The immunotherapy-related skin toxicities can significantly impede the patient's emotional, physical, social, and financial well-being resulting in a poor QoL. In rare cases of severe cutaneous reactions, treatment modifications are needed, resulting in a diminished overall survival. Important organizations in the field of oncology and supportive care, such as the MASCC, the ASCO, and the ESMO, have developed guidelines for the management of cancer therapy- related cutaneous toxicities based on available scientific evidence. Still, for some interventions, the evidence of recommendation is moderate to insufficient. Therefore, it is essential to elucidate other new potential management strategies for dermatological complications of cancer treatment. Based on the previously mentioned supportive care guidelines for the ImmunoSkin project, two novel skin care products to tackle the cutaneous adverse events of immunotherapy have been developed. The ImmunoSkin project general aim is to evaluate the efficacy of two novel skincare products to manage immunotherapy-related cutaneous toxicities.
Primary objective Evaluate the efficacy of two novel skin care products for the management of immunotherapy-related cutaneous adverse events Secondary objective 1 Evaluate patient-relevant treatment benefit of two novel skin care products for immunotherapy-related cutaneous toxicities Secondary objective 2 Evaluate the influence of two novel skin care products for immunotherapy-related cutaneous toxicities on the patient's quality of life Secondary objective 3 Evaluate the safety of two novel skin care products for immunotherapy-related cutaneous toxicities ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04929847 -
Novel Skin Care for Chemotherapy- Related Dermatologic Toxicities
|
N/A | |
| Not yet recruiting |
NCT03606954 -
Potency of Topical Corticosteroids in Combination Preparations
|
Phase 4 | |
| Completed |
NCT01976481 -
Serum 25-OH Vitamin D Modulation by Sunbed Use According to EU Guideline EN 60335-2-27
|
N/A | |
| Completed |
NCT03448731 -
Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)
|
Phase 2 | |
| Recruiting |
NCT05109858 -
Skin Toxicity by Oncological Therapies
|
||
| Completed |
NCT00871429 -
Skin Care for Cancer Patients: A Product Satisfaction Survey
|
N/A | |
| Recruiting |
NCT04469075 -
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
|
Phase 2 | |
| Recruiting |
NCT04650256 -
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences
|
N/A | |
| Terminated |
NCT01317433 -
Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer
|
N/A | |
| Active, not recruiting |
NCT03167268 -
Panitumumab Skin Toxicity Prevention Trial
|
Phase 2 | |
| Recruiting |
NCT06118047 -
Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
|
Phase 2 |